Penetration of antibody‐opsonized cells by the membrane attack complex of complement promotes Ca2+influx and induces streamers
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We have reported that during complement‐mediated cytolysis of B cells promoted by the CD20 mAbs rituximab or ofatumumab (OFA), long, thin structures that we call streamers (≥3 cell diameters) are rapidly generated and grow out from the cell surface. Streamers appear before cells are killed and contain opsonizing mAbs and membrane lipids. By exploiting the differential Ca 2+requirements of discrete steps in the complement cascade, we determined that mAb‐opsonized cells first tagged with C3b using C5‐depleted serum are killed on addition of serum and EDTA, but the cells do not produce streamers. Also, cells first opsonized with OFA are lysed in serum containing Mg‐EGTA by the alternative complement pathway but streamers are not produced. These findings indicate that Ca 2+influx is necessary for streamer formation. Other mAbs that promote complement‐mediated cytolysis also induce streamers on target cells. Streamer‐like structures called nanotubes have been reported in several cellular systems, and are thought to promote intercellular communication/signaling. We tested whether this signaling could influence the susceptibility of neighboring cells contacted by streamers to complement attack and found that complement‐mediated cytolysis of OFA‐opsonized cells increases the resistance of unopsonized indicator cell populations to subsequent lysis when these cells are exposed to OFA and complement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanotubular Highways for Intercellular Organelle Transport
Rustom, A., Saffrich, R., Markovic, I., Walther, P., & Gerdes, H.-H. (2004) · Science · doi:10.1126/science.1093133 · Cited by 2,038
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationRetroviruses can establish filopodial bridges for efficient cell-to-cell transmission
Sherer, N. M., Lehmann, M. J., Jimenez-Soto, L. F., Horensavitz, C., Pypaert, M., & Mothes, W. (2007) · Nature Cell Biology · doi:10.1038/ncb1544 · Cited by 432
Cited by
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Self-citationThe role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104
“Similarly, among a panel of anti-CD38 antibodies, only daratumumab was found to be a potent complement activator, although the epitope recognized by daratumumab overlaps with that of other antibodies that are poor activators, suggesting that, in this case, the specific orientation of daratumumab may allow for more eff…”
BackgroundSelf-citationTerminal complexes of the complement system: New structural insights and their relevance to function
Morgan, B. P., Walters, D., Serna, M., & Bubeck, D. (2016) · Immunological Reviews · doi:10.1111/imr.12461 · Cited by 58
Metadata
- Authors
- Beum, P. V., Lindorfer, M. A., Peek, E. M., Stukenberg, P. T., de Weers, M., Beurskens, F. J., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2011-07-04
- Volume
- 41
- Issue
- 8
- Pages
- 2436-2446
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2034274972
- Cited by
- 35
- References
- 4
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.